Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » Global Gaps in Access to Diagnostics and Treatment for Neuroendocrine Cancer Patients published in Journal of Neuroendocrinology

Global Gaps in Access to Diagnostics and Treatment for Neuroendocrine Cancer Patients published in Journal of Neuroendocrinology

  • June 22, 2023

The review article by INCA titled “Global Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients” was recently published in the Journal of Neuroendocrinology.

The author team comprises renowned NET experts including NeuroEndocrine Cancer Australia co-founder Simone Leyden and NET patient advocates from INCA member organizations. 

The article is based on the findings of the Survey of Challenges in Access to Diagnostics and Treatment for NET Patients (SCAN), which measured access to diagnosis, treatment and monitoring of neuroendocrine tumour (NET) patients globally.

SCAN surveyed 2359 patients and 436 healthcare professionals worldwide and revealed issues with access to NET diagnostic facilities and treatment in emerging and developing economies compared to advanced economies. Access to diagnostics and treatments for NETs varies worldwide due to inequalities in availability and affordability of diagnostic facilities/techniques, and treatment modalities, as well as diagnosis waiting time and misdiagnosis, and suboptimal care. Development of national care pathways, mandatory expert center referral, and improved understanding of the disease are critical for achieving earlier diagnosis and optimal NET care for all. Tackling accessibility and affordability issues, especially in emerging and developing economies (EDE), is key to minimizing access disparities.

Raising awareness amongst primary care physicians/GPs and other healthcare professionals that NETs tend to present with non-specific symptoms that may be attributed to more common conditions is also imperative to further improve NET care.

SCAN findings aim to contribute to positioning NET research on an equal footing with other cancers of similar prevalence and the results are crucial to improving patient survival and NET care worldwide.

Read the article published in the Journal of Neuroendocrinology HERE
Sugandha Dureja, Mark McDonnell, Dirk Van Genechten, Catherine Bouvier, Teodora Kolarova, Dermot O’Toole, Harjit Singh, Jie Chen, James Howe, Simron Singh … See all authors 
First published: 30 May 2023
https://doi.org/10.1111/jne.13310
 
Peer Review The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jne.13310.
 
PDFPDF
 

Share this post

Recent posts

BioPharmaDispatch 2025: Putting NETs on the National Agenda

May 27, 2025

WA Cancer Forum

May 27, 2025

ANZSNM 55th annual conference in Melbourne – Australia

May 27, 2025

NECA Strategy Day 2025

May 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousAdelaide NET Patient Forum
NextSenate moves motion to establish rare cancer inquiryNext

Related Posts

BioPharmaDispatch 2025: Putting NETs on the National Agenda

BioPharmaDispatch 2025: Putting NETs on the National Agenda NeuroEndocrine Cancer Australia was proud to attend the BioPharmaDispatch 2025 Conference in Sydney this month, represented by

WA Cancer Forum

The Cancer Network WA, in collaboration with the WA Clinical Oncology Group at Cancer Council WA,  held its second annual one-day symposium “Cancer Network Forum

ANZSNM 55th annual conference in Melbourne – Australia

Thank you to Simone Leyden AM, Director Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals Limited ARCS Australia, for organising sponsorship for a group

NECA Strategy Day 2025

On Wednesday 21 May, NeuroEndocrine Cancer Australia (NECA) hosted our annual Strategy Day in Sydney. It’s the one day each year when our entire team

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin